Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 8/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1667168 | 0.87 | GPR119 (0.55) | TBK1GPR119AAK1PDE4BIKBKE | |
| SCHEMBL17631454 | 0.84 | AAK1 (0.46) | TBK1GPR119AAK1PDE4B | |
| SCHEMBL18348317 | 0.83 | TBK1 (0.52) | TBK1GPR119AAK1PDE4BIKBKE | |
| SCHEMBL17645008 | 0.83 | AAK1 (0.45) | TBK1GPR119AAK1PDE4BIKBKE | |
| SCHEMBL31402999 | 0.81 | RET (0.48) | GPR119RET | |
| SCHEMBL17630409 | 0.79 | TBK1 (0.44) | TBK1GPR119AAK1PDE4BIKBKE | |
| SCHEMBL17630410 | 0.79 | TBK1 (0.44) | TBK1GPR119AAK1PDE4BIKBKE | |
| SCHEMBL2277773 | 0.78 | USP30 (0.44) | TBK1GPR119AAK1PDE4B | |
| SCHEMBL17645042 | 0.77 | TBK1 (0.43) | TBK1GPR119AAK1PDE4BIKBKE | |
| SCHEMBL14873109 | 0.77 | GPR119 (0.45) | TBK1GPR119AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025021182-A1 | CYP11A1 INHIBITORS | ACERAND THERAPEUTICS (HONG KONG) LIMITED (CN) | 2025-01-30 | — | — | WO | disclosed |